Lower doses than weight loss protocols, aimed at different goals. A gentler entry point, a maintenance route after reaching a target, or metabolic support where full dose therapy is not the objective.
Full dose GLP-1 therapy is aimed at substantial weight reduction and has a large trial base behind it. Microdosing uses the same medication class at lower doses toward different ends: easing into treatment, holding a result after reaching a goal, or supporting metabolic markers where major weight loss is not the aim.
The mechanism is the same. The evidence base is not. Full dose protocols were studied extensively and microdosing has been studied considerably less, which is a distinction we would rather state than blur.
Microdosing suits three fairly different situations, and which applies to you changes the protocol entirely.
Some people are put off full dose therapy by the side effect profile. Beginning lower can make treatment tolerable for someone who would otherwise not start at all, or would stop in the first fortnight.
Weight regain after stopping GLP-1 therapy is well documented. Lower dose maintenance is one approach to that problem, and it is an active area rather than a settled one.
Some people pursue lower dose therapy for metabolic markers rather than weight. The evidence here is thinner still, and expectations need setting accordingly.
A lower dose does not mean lower screening. The same contraindications apply, and evaluation is no less thorough than for full dose therapy.
This is having a commercial moment, and the evidence has not caught up with the enthusiasm.
The large trials that established this medication class used the full dosing protocols. Microdosing borrows credibility from that evidence while operating at doses those trials did not study, and that gap deserves naming.
Using lower doses to hold a result after weight loss is a reasonable hypothesis and an active area of practice. It is not something with a settled evidence base, and we will describe it that way.
These remain prescription medications with real contraindications and real side effects. Lower dosing does not change what the medication is, and the screening reflects that.
Screened identically to full dose therapy, and not appropriate for everyone.
People put off full dose therapy by the side effect profile
Anyone who reached a weight goal and wants to discuss maintenance
People whose aim is metabolic markers rather than major weight loss
Anyone who wants the evidence gap stated rather than glossed over
Not appropriate with a history of medullary thyroid carcinoma or MEN 2
Not appropriate with pancreatitis history, in pregnancy, or while breastfeeding
Four steps, and screening is no lighter than for full dose therapy.
History, medications, previous GLP-1 experience, and what you are aiming for.
Which use applies to you, and whether treatment is appropriate at all.
What is established for full dose therapy and what is not established at lower doses.
Where prescribed, with supervision and a defined point to reassess.
This describes the programme rather than any outcome. Individual response varies considerably.
Lower dosing than established weight loss protocols
Used as an entry point, for maintenance, or for metabolic support
Screening identical to full dose therapy
The evidence gap between full and low dose stated plainly
Physician supervision throughout
Contraindications assessed rather than assumed
A defined point to reassess rather than open ended supply
A clear no where treatment is not appropriate
Being clear about the arrangement, because most sites in this category are not.
Longevity Gyms is a non clinical performance and recovery facility. We do not prescribe medication or provide medical care. Care within Vitality is delivered by licensed physicians through our telehealth infrastructure partner, and your clinical relationship is with that practice. Compounded medications are not evaluated or approved by the FDA for safety, efficacy or quality. Availability varies by state.
Dose and intent. Full dose protocols aim at substantial weight reduction and have a large trial base. Microdosing uses lower doses toward different goals, with considerably less evidence behind it.
For tolerability and as a maintenance approach there is reasonable clinical rationale. For metabolic support at low doses the evidence is thinner. We will tell you which situation you are in.
Lower doses generally mean fewer side effects, but the contraindications are identical and screening is no lighter. It is a different dose of the same medication, not a different medication.
That is one of the main reasons people ask about it, given how well documented regain is after stopping. It is an active area of practice rather than a settled protocol, and we will describe it that way.
Not to the extent full dose therapy produces, and that is generally not the aim. If substantial weight loss is your goal, full dose therapy is the better conversation.
Because the large trials studied full dosing protocols. Microdosing operates at doses those trials did not examine, which is a real gap rather than a technicality.
Yes, identically. The same contraindications apply and the evaluation is no less thorough.
Availability varies by state and is confirmed during your evaluation before you commit.
A licensed physician through our telehealth infrastructure. Longevity Gyms does not prescribe medication.
Frequently assessed together, since these areas overlap more than most people expect.
The evaluation takes about fifteen minutes and starts with which question you are asking. In it you will: